Vanguard Investments Australia
SLNO

Vanguard Investments Australia’s Soleno Therapeutics SLNO Stock Holding History

Vanguard Investments Australia’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,508
Closed -$385K – 2418
2026
Q1 		$385K Buy
+11,508
New +$451K ﹤0.01% 1712

Vanguard Investments Australia's SLNO Position: Q2 2026 in Review

Vanguard Investments Australia sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 11,508 shares — an estimated $385K sold.

Vanguard Investments Australia first reported a position in SLNO in Q1 2026 and held it in 1 quarter. The position peaked at $385K in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Vanguard Investments Australia reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vanguard Investments Australia sold 11,508 Soleno Therapeutics shares in Q2 2026, an estimated $385K.
  • Vanguard Investments Australia first reported a position in Soleno Therapeutics in Q1 2026 and held it in 1 quarter.
  • Vanguard Investments Australia's Soleno Therapeutics position peaked at $385K in Q1 2026.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.